Paolo Augusto Paoletti
Director/Board Member at GENMAB A/S
Net worth: 586 219 $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jan van de Winkel | M | 63 | 25 years | |
| Deirdre Connelly | F | 63 | 14 years | |
| Phil Thomson | M | - | 13 years | |
| Edward F. Patz | M | - |
Grid Therapeutics LLC
 Grid Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Grid Therapeutics LLC develops and research cancer therapeutics to develop human derived antibodies. Its pipeline drugs include GT103 recombinant complement factor H monoclonal antibody and GT-20(x) recombinant monoclonal antibody. The company was founded by Edward F. Patz, Jr., Michael John Campagna and Elizabeth B. Gottlin and is headquartered in Chapel Hill, NC. | - |
| Emma Walmsley | F | 55 | 14 years | |
| Martine van Vugt | M | 71 | 23 years | |
| Tahamtan Ahmadi | M | 51 | 7 years | |
| Pernille Erenbjerg | F | 57 | 9 years | |
| Marisol Peron | F | - | 5 years | |
| Jeannette Potts | M | 62 | 5 years | |
| Anthony Pagano | M | 46 | 17 years | |
| Elizabeth O'Farrell | F | 59 | 2 years | |
| Howard Davis | M | - |
Akamis Bio Ltd.
 Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | 2 years |
| Rolf K. Hoffmann | M | 64 | 8 years | |
| John Duncan Higgons | M | 69 |
Akamis Bio Ltd.
Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | - |
| Thomas L. Patz | M | 63 |
Grid Therapeutics LLC
Grid Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Grid Therapeutics LLC develops and research cancer therapeutics to develop human derived antibodies. Its pipeline drugs include GT103 recombinant complement factor H monoclonal antibody and GT-20(x) recombinant monoclonal antibody. The company was founded by Edward F. Patz, Jr., Michael John Campagna and Elizabeth B. Gottlin and is headquartered in Chapel Hill, NC. | - |
| Christopher Cozic | M | 46 | - | |
| Ezra Cohen | M | - |
Akamis Bio Ltd.
Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | - |
| Ruth du Moulin | F | - | 4 years | |
| Anthony Mancini | M | 53 | 4 years | |
| Martin Schultz | M | 49 | 2 years | |
| Takahiro Hamatani | M | 50 | 2 years | |
| Frannie DeFranco | F | - | 14 years | |
| Mijke Zachariasse | M | 51 | 5 years | |
| Judith Klimovsky | M | 67 | 7 years | |
| María Cristina de Luna Basagoiti | F | - | 14 years | |
| David N. Cook | M | 66 | 4 years | |
| Richard Parker | M | - |
Grid Therapeutics LLC
Grid Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Grid Therapeutics LLC develops and research cancer therapeutics to develop human derived antibodies. Its pipeline drugs include GT103 recombinant complement factor H monoclonal antibody and GT-20(x) recombinant monoclonal antibody. The company was founded by Edward F. Patz, Jr., Michael John Campagna and Elizabeth B. Gottlin and is headquartered in Chapel Hill, NC. | - |
| Kevin A. Schulman | M | - |
Grid Therapeutics LLC
Grid Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Grid Therapeutics LLC develops and research cancer therapeutics to develop human derived antibodies. Its pipeline drugs include GT103 recombinant complement factor H monoclonal antibody and GT-20(x) recombinant monoclonal antibody. The company was founded by Edward F. Patz, Jr., Michael John Campagna and Elizabeth B. Gottlin and is headquartered in Chapel Hill, NC. | - |
| Brian Champion | M | - |
Akamis Bio Ltd.
Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | - |
| Tracey Adamson | F | - |
Biomed Ltd.
 Biomed Ltd. Pharmaceuticals: MajorHealth Technology Biomed Ltd. manufactures pharmaceutical products. The company is headquartered in Auckland, New Zealand. | - |
| Matthew Foy | M | - |
Akamis Bio Ltd.
Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | - |
| Victoria Whyte | F | - | 15 years | |
| Todd Shegog | M | 59 | 5 years | |
| Birgitte Stephensen | F | 63 | 22 years | |
| Graeme Scott Hawkins | M | - |
Biomed Ltd.
Biomed Ltd. Pharmaceuticals: MajorHealth Technology Biomed Ltd. manufactures pharmaceutical products. The company is headquartered in Auckland, New Zealand. | - |
| Andrew Carlsen | M | - | 5 years | |
| Samuel Cameron Williams | M | 55 |
Akamis Bio Ltd.
Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | - |
| Mette Agger | F | 59 |
Akamis Bio Ltd.
Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | - |
| Anders Gersel Pedersen | M | 73 | 21 years | |
| Mario Corso | M | - | 4 years | |
| Anita Kidgell | F | - | 16 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Mats Gunnar Pettersson | M | 78 | 7 years | |
| Philip Hampton | M | 70 | 4 years | |
| Thomas Mount | M | - | 7 years | |
| Frank Lee | M | 56 | 3 years | |
| Michael A. Foley | M | 62 | 9 years | |
| Daniel John Bruno | M | 45 | - | |
| Rachel Curtis Gravesen | F | 55 | 8 years | |
| Jing Ulrich | F | 56 | - | |
| Judy Lewent | F | 75 | 10 years | |
| Michael K. Bauer | M | 60 | 14 years | |
| Selwyn Vickers | M | 64 | 1 years | |
| Jonathan Peacock | M | 66 | 1 years | |
| Hans Henrik Munch-Jensen | M | 64 | 8 years | |
| Wayne Frederick | M | 52 | 2 years | |
| Anjali Bansal | F | 53 | 6 years | |
| Michal Silverberg | F | 48 | 3 years | |
| Balbir Kelly Bisla | F | - | 4 years | |
| Ravi Rao | M | 55 | 7 years | |
| Patrick F. Kelly | M | 60 | 6 years | |
| Peter Kolchinsky | M | 47 | 3 years | |
| Daniel Bach | M | - |
Akamis Bio Ltd.
Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | - |
| Steve Hall | M | 69 | 11 years | |
| Stacey Cartwright | F | 60 | 5 years | |
| Jean-Pierre Garnier | M | 75 | 8 years | |
| H. Culp | M | 60 | 9 years | |
| Burt Malkiel | M | 90 | 11 years | |
| Ian Maurice Gray Prosser | M | 81 | 9 years | |
| Robert Wilson | M | 81 | 11 years | |
| Lynn Elsenhans | F | 68 | 10 years | |
| Christopher Gent | M | 75 | 11 years | |
| James Murdoch | M | 51 | 3 years | |
| Crispin Davis | M | 75 | 10 years | |
| Robert Carr | M | - | 26 years | |
| Thomas Wiggans | M | 72 | 2 years | |
| Urs Rohner | M | 65 | 9 years | |
| Gerardus Johannes Wijers | M | 74 | 3 years | |
| Timothy Clackson | M | 58 | 4 years | |
| Simon Dingemans | M | 61 | 8 years | |
| Julian Heslop | M | 70 | 13 years | |
| Christopher Viehbacher | M | 64 | 20 years | |
| Tonya Williams | F | 50 | 1 years | |
| Filippo Lanzi | M | - | 9 years | |
| Jay Green | M | 52 | 6 years | |
| Jing Ji | M | 54 | 4 years | |
| Hu Li | M | 59 | 19 years | |
| Jane Hughes | M | 50 | 3 years | |
| Min Li | M | 62 | 6 years | |
| Cedrik M. Britten | M | 49 | 5 years | |
| Martin Andrews | M | 61 | 10 years | |
| Atul Pande | M | 69 | 7 years | |
| Anne Michelle Whitaker | F | 56 | 3 years | |
| Elyse G. Seltzer | M | 59 | 6 years | |
| Abid Ansari | M | 46 | 5 years | |
| Kim Sablich | F | 55 | 8 years | |
| Pearl Shirley Huang | M | 66 | 2 years | |
| Michael G. Moore | M | - |
Akamis Bio Ltd.
Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | - |
| Michael Owen | M | 73 | 9 years | |
| Imran Eba | M | - | 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United Kingdom | 55 | 55.00% |
| Denmark | 25 | 25.00% |
| United States | 19 | 19.00% |
| New Zealand | 2 | 2.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Paolo Augusto Paoletti
- Personal Network
